EGM Shareholder Presentation
Released
Released
Announcement PDF
ASX: PAA
EGM Presentation
February 2024
Dr Michael Thurn
Disclaimer
This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by PharmAust Limited (ASX: PAA) (the “Company”). It does not purport to
contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any
information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of
the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this
presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent
decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute
discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this
presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations
Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or
similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in
isolation as a basis to invest in the Company.
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and
prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The
performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that
any particular rate of return will be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended,
recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results,
performance or achievements will be as expected, planned or intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as
defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of
any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from
registration including an exemption for qualified institutional buyers.
2
EGM Presentation
Corporate Overview
Mid-stage biotechnology company targeting human neurodegenerative diseases
Share Price Performance
Capital Structure (AUD$)
Volume (m)
Last Price (AUD$)
0.25
14
Volume
PAA
12
0.20
10
0.15
1-Apr-23
1-Jun-23
1-Aug-23
1-Oct-23
1-Dec-23
1-Feb-24
52 Week Low / High (PAA)
$0.06/ $0.26
No. of Shares (PAA)
384,965,597
Listed Options (PAAOA)
121,949,093
Monthly Turnover
$4.9m
6
Cash (as at 31-Dec-23)
$5.5 m
4
Debt (as at 31-Dec-23)
Nil
2
Net Cash
$5.5m
-
Enterprise Value
$22.4m
Unlisted Options (10c/15c/17.5c)
Enterprise Value (fully diluted)
Board & Management
3
$0.23 / $0.13
$69.2m
0.05
0.00
1-Feb-23
Current Share Price (PAA/PAAOA)
Market Capitalisation
8
0.10
16 Feb 2024
11.4 m
$63.7m
Dr Roger Aston
Non-Exec Chairman
Top Shareholders*
Dr Michael Thurn
Chief Executive Officer
Hybrid Holdings Pty Ltd <Darcy Family Super Fund A/C>
Mr Neville Bassett AM
Non-Exec Director
Mr Gerald James Van Blommestein & Mrs Gillian Van
Mr Robert Bishop
Non-Exec Director
Blommestein <Van Blommestein S/F A/C>
Dr Thomas Duthy
Non-Exec Director
Dr Roger Aston
3.91%
Mr Sam Wright
Non-Exec Director & Company Secretary
Board & Management
7.84%
* As at 16 Feb 2024
5.78%
4.75%
EGM Presentation
Product candidates for both human and animal health applications
Human and Animal Health
Mid stage biotechnology company
focused on large and growing markets
in human and animal health
Strong intellectual property with
patent protection beyond 2030
Repurposing Monepantel
Pipeline Synergies
Repurposing an approved veterinary
product – monepantel – anthelmintic
for sheep
Pipeline synergies to leverage
commercial infrastructure across
human and animal health applications
Motor Neurone Disease
Experienced Management
Lead clinical program for the
treatment of motor neurone disease
(MND/ALS)
Experienced management team with
demonstrated execution capabilities
Canine B-Cell Lymphoma
Broad Investor Base
Phase 2 Veterinary program for the
treatment of dogs with B-Cell
Lymphoma
4
Strong IP Position
Healthy mix of loyal institutional and
retail investors
EGM Presentation
Meet Our Team – Chairman and Management
Dr Roger Aston
Non-Executive Chairman
Roger brings more than 30 years
experience in the pharmaceutical and
healthcare industries in senior roles in
the UK, Asia Pacific and Australia. He has
had extensive experience including FDA
and EU product registration, clinical
trials, global licensing agreements,
fundraising through private placements,
and a network of contacts within the
pharmaceutical, banking and stock
broking sectors
5
Dr Michael Thurn
Chief Executive Officer
Michael has over 25 years experience in
technical, regulatory, commercial and
management roles in research
organisations and industry, including
early stage, fast growing, private and
publicly listed biotechnology companies.
Michael has led a variety of US IND
applications across a range of
therapeutic areas and evaluated drugs
and vaccines for registration during his
engagement at the TGA.
John Clark
Chief Operating Officer
John has over 20 years of
pharmaceutical industry experience in
phase I – IV clinical trials across
numerous therapeutic areas and
multiple geographical regions. John has
a thorough knowledge of ICH-GCP and
regulatory requirements and held
clinical operations leadership roles
responsible for implementing global
clinical programs.
Dr Carol Worth
CMC Operations Manager
Carol brings over 30 years of industry
experience and a passion for focusing
on quality control and quality assurance.
She recently served as Quality Manager
at Epichem Pty Ltd as Chief Technical
Officer at Suda Pharmaceuticals and
Solbec Pharmaceuticals. Carol has also
led product development programs at
Thermalife International Pty Ltd/
Pharmasolv Laboratories Pty Ltd
EGM Presentation
Pipeline
Multiple synergistic product opportunities in human and animal health by repurposing monepantel
Human Health
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved /
Marketed
Accelerated approval
possible based on
Phase 2 data
Motor Neurone
Disease
(Amyotrophic Lateral Sclerosis)
Next Major Catalysts
• Phase 1 Top-line Results Q1 2024
• Orphan Drug Designation
• Open IND
• Under review
• Seek partnership opportunities
Cancers
Animal Health
Indication
Preclinical
Canine B-Cell
Lymphoma
Cancers
Phase 1
Phase 2
Field Study / TASS
Approved /
Marketed
Conditional
approval possible
Next Major Catalysts
• MUMS Waiver
• Open INAD
• Begin Field Study
• Under review
• Seek partnership opportunities
IND – Investigational New Drug
MUMS – Minor Use Minor Species
INAD – Investigational New Animal Drug
TASS – Target Animal Safety Trial
6
EGM Presentation
MND /ALS Statistics & Treatments
There is no cure and MND/ALS is always fatal
Every 90 minutes
someone is
diagnosed and
dies with MND/ALS
90% of cases
occur without
a family
history
Onset is usually
between the ages of
40 & 70 years
Life expectancy on
average is just over
2 years
By 2040 the incidence
of MND/ALS is
expected to increase
by 70%
Current
Treatments
Qalsody (tofersen)
Developed to treat ALS associated with a
mutation in the superoxide dismutase 1
(SOD1) gene. The FDA approved Qalsody to
treat SOD1-ALS in 2023.
Rilutek (riluzole)
This was the first FDA-approved
drug available to treat ALS — in
1995. It inhibits glutamate release
and prolongs life ~3 months.
Radicava (edaravone)
The FDA approved Radicava
in 2017, making it the first new
treatment specifically for ALS in 22
years. Prolongs life ~6 months.
Relyvrio (AMX0035)
RELYVRIO is a combination of two
drugs, sodium phenylbutyrate and
taurursodiol. The FDA approved
RELYVRIO for use to treat ALS in
2022. Prolongs life ~ 9 months.
These drugs provide limited relief and slow disease progression by only months
7
EGM Presentation
MND /ALS Pathology & Disease Progression
Characterised by progressive degeneration of nerve cells in the spinal cord and brain, MND/ALS affects the
voluntary control of the arms and legs, eventually leading to trouble with breathing and death
Normal Neuron
Mislocalization
Genetic factors
Environmental
factors
Aggregation
Monepantel
promotes autophagy
Degeneration
Autophagy is the natural
process the cell uses to
removes unnecessary or
dysfunctional or toxic
components through a
lysosome-dependent
regulated mechanism
Protein aggregation1 is an important feature of MND/ALS pathology. Amyloid deposits from different proteins such as TDP-43, C9ORF72 dipeptide
repeats, phosphorylated high molecular weight neurofilament protein, rho guanine nucleotide exchange factor, and FUS have been detected in MND/ALS
motor neurons. These aberrant protein deposits become toxic to the cells, leading to neurodegeneration and are targets for therapeutic interventions.
1Suk, T.R., Rousseaux, M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegeneration 15, 45 (2020). https://doi.org/10.1186/s13024-020-00397-1
8
EGM Presentation
Monepantel Induces Autophagy
Accumulating evidence suggests that impaired autophagy contributes to the accumulation of intracellular inclusion
bodies consisting of misfolded proteins, which is a hallmark of most neurodegenerative diseases
Control
Monepantel
(25 µM)
A2780 ovarian
cancer cells
U87-MG glioma
cells
Arrows depict autophagolyosomes (small lysosomal sacs or vacuoles that breaks down the cellular junk in our cells during the process of autophagy)
9
EGM Presentation
Phase 1
MND/ALS Study
The Phase 1 MEND Study is an open label, multicentre study involving 12 patients with MND/ALS with the goal of
determining the recommended Phase 2 dose based on safety and preliminary efficacy
Study Design
Cohort 2
4 mg/kg
Group 1
6 Patients
Cohort 1
2 mg/kg
End of
Study
Group 2
6 Patients
SMC
SMC
Continue Treatment
Continue Treatment
Cohort 3
6 mg/kg
Cohort 4
10 mg/kg
Compassionate-use
Program
SMC
Day 1
Open-Label Extension Study
12-months 10 mg/kg
Continue Treatment
12 Months
16 Months
28 Months
Treatment Period
SMC Safety Monitoring Committee
Study
Update
SMC
• Analysis near completion to support release of top-line data by end of Q1 CY24
• All patients willing and able to roll-over into 12-month Open-Label Extension Study
• Patients have continued treatment with monepantel under a compassionate-use program
• Treatment continues to be very well-tolerated
• First Group of 6 patients entering their 16 month of continuous treatment with monepantel
• Data will be used to support the Orphan Drug Designation application and to open an IND with the US FDA to commence an
adaptive Phase 2/3 Study in H1 CY24
10
EGM Presentation
Phase 1
MND/ALS Study
Statistical survival estimations based on comparisons to the PRO-ACT1 historical ALS database, points to the
probability that all 12 patients treated with monepantel being alive today being less than 1 in 1,000
Berry Consultants Statistical Analysis
Overall Survival Probability
• One-year study survival rate estimate of 67.7% with a 95%
Confidence Interval
• Considering differential diagnosis durations, the probability estimates
of all 12 Phase 1 MEND patients surviving today without treatment
are less than 0.1% (less than 1 in 1,000)
Probability
• Berry’s analysis involved comparing patients in the PRO-ACT
database with similar characteristics to those in PharmAust’s Phase
1 MEND Study adjusting for differing diagnosis durations
Current
patients
PRO-ACT
database
Days on treatment with monepantel
The PRO-ACT database is the largest publicly available repository of merged ALS
clinical study data. Data were pooled from 16 completed Phase 2/3 ALS clinical
studies and one observational study. Over 8 million de-identified longitudinally
collected data points from more than 8,600 persons with ALS, including
demographics, family histories, and longitudinal clinical and laboratory data.
1Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov
4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834.
11
EGM Presentation
Phase 1
Amyotrophic Lateral Sclerosis Function Rating Score – Revised (ALSFRS-R)
ALSFRS-R is a predictor of survival time in ALS patients.1 The speed at which ALS progresses, measured by the rate of
decline in a patient’s ALSFRS-R score over time, can be used to confidently predict disease prognosis.
ALSFRS-R Domains Assessed
AMX0035 – 25% Slower Decline in ALSFRS-R
Bulbar
• Speech
• Salivation
• Swallowing
Respiratory
• Dyspnea
• Orthopnea
• Respiratory
insufficiency
Fine Motor
Gross Motor
• Turning in bed
• Walking
• Climbing Stairs
• Handwriting
• Cutting food
• Dressing & hygiene
Each task is rated on a five-point scale from 0 = can't do, to 4 =
normal ability. Individual item scores are summed to produce a
reported score of between 0=worst and 48=best.
12
1Beghi E, Mennini T, Bendotti C, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14(30):3185-3200
Slowing the decline
in ALSFRS-R by
16.5%
2Leigh PN, Swash M, Iwasaki Y, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(2):84-98
=
4-5 months
median
survival2
EGM Presentation
MND/ALS Progression Statistics
About 50% of patients with ALS live at least 3 years or more after diagnosis; 20% live 5 years or more; and up to 10%
survive for more than 10 years1
MND / ALS Progression – Typically 2-3 years2,3
Symptom
Onset
Progressive Weakness
Survival
Diagnosis
Difficulty
walking
Slurred
Speech
Wheelchair
Part-time
caregiver
Difficulty
Swallowing
Feeding Tube
Non-invasive
ventilation
Full-time
caregiver
Permanent
assisted
ventilation
Death
• Median survival ~2 years from diagnosis4
• Time to diagnosis on average is 12 months in the US2
• Population-based prospective registries report 1 year mortality rates after diagnosis ranging from 22% to 34%5
• Shortest time since diagnosis ~16 months compared to the longest ~49 months for the completed Phase 1 MEND Study
1Cruz MP. Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. P T. 2018 Jan;43(1):25-28. PMID: 29290672; PMCID: PMC5737249.
2Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4(7):605-618. doi: 10.4155/cli.14.52. PMID: 28203356; PMCID: PMC5305182.
3Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG; Eurals Consortium. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23. doi: 10.3109/17482960802566824. PMID: 19922118; PMCID: PMC3515205.
13
4Karanevich, A.G., Statland, J.M., Gajewski, B.J. et al. Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. BMC Med Res Methodol 18, 19 (2018). https://doi.org/10.1186/s12874-018-0479-92
5Wolf, J., Safer, A., Wöhrle, J.C. et al. Factors predicting one-year mortality in amyotrophic lateral sclerosis patients - data from a population-based registry. BMC Neurol 14, 197 (2014). https://doi.org/10.1186/s12883-014-0197-9
EGM Presentation
Pre-IND Meeting Response
Successfully completed a Pre-IND meeting with the FDA to confirm the details of the ongoing development program,
including the requirements for non-clinical and clinical pharmacology, clinical, chemistry, and manufacturing controls
Global Phase 2/3 Clinical Study
Specific FDA Feedback and Guidance
• FDA provided positive feedback and outlined the path required to
potentially receive accelerated and full approval of monepantel for
the treatment of ALS
• PharmAust will initiate requirements requested by the FDA in the
preparation to open an IND application for the adaptive Phase 2/3
clinical study
• PharmAust will now prepare to launch clinical sites in Europe and
Australia where data can also be used to support the FDA drug
approval process
• Registration in Europe and Australia now possible with this global
approach
Single clinical study sufficient
subject to demonstrating substantial evidence of effectiveness and an adequate database supporting safety
14
EGM Presentation
Rare Central Nervous System disease market
The global CNS rare disease treatment market is expected to reach US$13.8 billion by 2027 (CAGR > 8.5%)1
Selected partnering deals in the CNS field in 20232
Neurological disease deals by therapy type in 2022 and 2023 (October)2
Date
Stage
Companies
Jul 2023
Phase 3
Biogen / Reata
Pharmaceuticals
Mar 2023
Phase 1
Sep 2023
Preclinical
Deal Value
Target
US$7.3 Billion Acquisition
Omaveloxolone
Biohaven / Hangzhou
Highlightll
US$970 Million License
BHV-8000
Takeda / Acurastem
US$580 Million License
AS-202
•
•
•
Reata just launched Skyclarys
(omaveloxolone) in US, under
regulatory review in Europe to
treat Friedreich’s ataxia
US$20 million in cash and
equity upfront , development
and commercial milestones.
tiered royalties
Combined upfront payment
and milestones could reach
US$580 million in total,
alongside royalties
•
•
•
Possesses
antioxidative and
anti-inflammatory
activities
Dual Tyrosine
Kinase 2
(TYK2)/Janus
Kinase 1 (JAK1)
inhibitor
PIKFYVE-targeted
antisense
oligonucleotide
Over 49 deals were announced 2023 involving rare CNS diseases, with disclosed
deal values totalling more than US$13.2 billion
1The Insight Partner March 2020
15
2Mark Zipkin, Neurodegeneration and rare diseases drive CNS therapy deals. Biopharma Dealmakers News Feature. 1 December 2023. doi: https://doi.org/10.1038/d43747-023-00128-7
EGM Presentation
MND R&D timeline
Timeline
•
MEND Study Patient Completes
•
ODD Submission
•
Management Hires
•
Compassionate-use Program
•
FightMND Grant Invitation
Q4
CY2023
Q1
CY2024
•
ODD Response
•
Open IND Phase 2 MND Study
•
Phase 2/3 Study HREC
Approval
•
First Patient Dosed MND Study
•
Pre-IND Meeting Request
•
Berry Consultants Partnership
•
OLE Study HREC Approval
•
MEND Study Top-line Results
•
SAB Appointments
Q2
CY2024
IND – Investigational New Drug; ODD – Orphan Drug Designation; OLE – Open Label Extension; SAB – Scientific Advisory Board
16
EGM Presentation
ASX: PAA
Registered Address:
Suite 116, 1 Kyle Way, Claremont WA 6010
Australia
Phone: +61 (8) 9202 6814
Email: investorenquiries@pharmaust.com
Share your feedback
Discover